v3.24.2.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
 6 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net loss $ (4,758,936) $ (4,844,910) $ (9,212,417) $ (1,998,055)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation 9,429 12,306 24,889 3,863
Issuance of common stock for services 1,224,900 1,087,000 1,530,651 540,065
Imputed interest expense (6,473) 6,473
Other income     (6,473)
Options vested for stock-based compensation 88,945 128,542 624,463 234,088
Loss on sale of assets 18,387    
Amortization of discount on preferred stock 222,678    
Warrants for service cancelled     (151,821)
(Increase) decrease in operating assets:        
Rent Deposits     (16,942)
Inventory 4,482 (23,494) (18,501)
Prepaid expenses 47,654 (41,015) (49,208) (11,745)
Operating lease right of use asset 29,251 27,082 54,979 (174,241)
(Decrease) increase in operating liabilities:        
Accounts payable and accrued liabilities     107,090 33,675
Operating lease right of use liabilities (31,134) (27,862) (56,726) 185,405
Payroll tax liabilities (1,908) 3,408 3,878 2,717
NET CASH USED IN OPERATING ACTIVITIES (2,568,367) (3,588,886) (6,997,375) (1,346,518)
CASH FLOWS FROM INVESTING ACTIVITIES:        
Purchases of property and equipment (3,519) (3,519) (43,102)
Sale of property and equipment 65,000    
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES 65,000 (3,519) (3,519) (43,102)
CASH FLOWS FROM FINANCING ACTIVITIES:        
Proceeds from borrowings on notes payable to related parties 187,500 75,000
Proceeds from sales of preferred stock for cash 1,500,000    
Proceeds from exercise of warrants 1,024,500    
Repayment on notes payable (78,260) (78,260)
Repayment on notes payable - related party (89,200) (89,200) (25,070)
Proceeds from exercise of warrants     1,024,500
Proceeds from sales of common stock for cash 568,270 5,000,000 6,200,000 2,000,000
NET CASH PROVIDED BY FINANCING ACTIVITIES 2,255,770 5,857,040 7,057,040 2,049,930
End of period (247,597) 2,264,635 56,146 660,310
CASH AND CASH EQUIVALENTS:        
Beginning of period 739,006 682,860 682,860 22,550
Effects of currency translation on cash and cash equivalents (1,166)    
End of period 490,243 2,947,495 739,006 682,860
Supplemental disclosure of cash flow information:        
Cash paid for income taxes
Cash paid for interest
Supplemental schedule of non-cash investing and financing activities:        
Issuance of Series C Convertible Preferred for patent acquisition 14,610,000    
Series B Convertible Preferred converted to common stock 390,500    
Nonrelated Party [Member]        
(Decrease) increase in operating liabilities:        
Accounts payable and accrued liabilities 577,885 96,530    
Related Party [Member]        
(Decrease) increase in operating liabilities:        
Accounts payable and accrued liabilities